Publication

Article

CURE

Winter 2013
Volume12
Issue 4

Poor Kidney Function a Possibility in Adult Survivors of Childhood Cancer

Long-term and late effects from toxic regimens from childhood cancer treatments include heart damage, lung problems and infertility.

As survival rates for many forms of childhoodcancer have climbed, more research isuncovering the tolls exacted for life-saving treatments.Long-term and late effects from toxictreatment regimens include heart damage, lungproblems and infertility.

A new study from the Netherlands reveals that certain cancer treatments, such as the chemotherapy drugs ifosfamide, cisplatin, carboplatin, high-dose methotrexate and high-dose cyclophosphamide, as well as renal radiation and removal of part or all of the kidney (nephrectomy), can affect a specific type of kidney function in adult survivors of childhood cancer.

The study examined the renal function of 1,122 survivors ages 18 and older. The researchers discovered that the kidney function of those treated with ifosfamide, high-dose cisplatin and nephrectomy began to decline most quickly. Ifosfamide is used to treat lymphomas and sarcomas, while cisplatin is used for retinoblastomas and brain tumors.

The researchers concluded that this long-term effect places survivors at risk for premature kidney failure and recommended that physicians be attentive to those who received some of the more toxic regimens.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Related Content